These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 37273452)
41. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma. Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL Front Immunol; 2021; 12():781087. PubMed ID: 35069553 [TBL] [Abstract][Full Text] [Related]
42. Survival‑related DLEU1 is associated with HPV infection status and serves as a biomarker in HPV‑infected cervical cancer. Dong A; Xu B; Wang Z; Miao X Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35014679 [TBL] [Abstract][Full Text] [Related]
43. Expression and clinicopathological significance of hematopoietic pre-B cell leukemia transcription factor-interacting protein in cervical carcinoma. Wang Y; Li D; Liu Y; Tian S; Chen X Pathol Res Pract; 2018 Sep; 214(9):1340-1344. PubMed ID: 30033330 [TBL] [Abstract][Full Text] [Related]
44. Comprehensive Analysis of Prognostic and Immune Infiltrates for RAD51 in Human Breast Cancer. Li F; Zhang Y; Shi Y; Liu S Crit Rev Eukaryot Gene Expr; 2021; 31(4):71-79. PubMed ID: 34587437 [TBL] [Abstract][Full Text] [Related]
45. Serum CCAT2 as a biomarker for adjuvant diagnosis and prognostic prediction of cervical cancer. Cao X; Yao J; Jia M; Shen X; Zhang J; Ju S J Ovarian Res; 2022 Feb; 15(1):20. PubMed ID: 35115025 [TBL] [Abstract][Full Text] [Related]
46. Connecting METTL3 and intratumoural CD33 Ni HH; Zhang L; Huang H; Dai SQ; Li J J Transl Med; 2020 Oct; 18(1):393. PubMed ID: 33059689 [TBL] [Abstract][Full Text] [Related]
47. Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis. Yang X; Cao JL; Yang FN; Li XF; Tao LM; Wang F Taiwan J Obstet Gynecol; 2021 May; 60(3):480-486. PubMed ID: 33966732 [TBL] [Abstract][Full Text] [Related]
48. Construction of an immune infiltration landscape based on immune-related genes in cervical cancer. Yang Y; Wang N; Shi X; Wang Y; Yang C; Fan J; Jia X Comput Biol Med; 2022 Jul; 146():105638. PubMed ID: 35605489 [TBL] [Abstract][Full Text] [Related]
49. m Jia H; Hao S; Cao M; Wang L; Bai H; Shui W; Yang X Dis Markers; 2022; 2022():8700372. PubMed ID: 35432630 [TBL] [Abstract][Full Text] [Related]
50. A novel ten-gene prognostic signature for cervical cancer based on CD79B-related immunomodulators. Pu D; Liu D; Li C; Chen C; Che Y; Lv J; Yang Y; Wang X Front Genet; 2022; 13():933798. PubMed ID: 36406115 [TBL] [Abstract][Full Text] [Related]
51. Identification of pyroptosis-related signature for cervical cancer predicting prognosis. Zhou C; Li C; Zheng Y; Liu X Aging (Albany NY); 2021 Nov; 13(22):24795-24814. PubMed ID: 34837692 [TBL] [Abstract][Full Text] [Related]
52. TCR Repertoire as a Novel Indicator for Immune Monitoring and Prognosis Assessment of Patients With Cervical Cancer. Cui JH; Lin KR; Yuan SH; Jin YB; Chen XP; Su XK; Jiang J; Pan YM; Mao SL; Mao XF; Luo W Front Immunol; 2018; 9():2729. PubMed ID: 30524447 [TBL] [Abstract][Full Text] [Related]
53. Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. Zheng Q; Wang Z; Zhang M; Yu Y; Chen R; Lu T; Liu L; Ma J; Liu T; Zheng H; Li H; Li J BMC Cancer; 2021 Nov; 21(1):1216. PubMed ID: 34774014 [TBL] [Abstract][Full Text] [Related]
54. Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin expression. Ancuţa E; Ancuţa C; Cozma LG; Iordache C; Anghelache-Lupaşcu I; Anton E; Carasevici E; Chirieac R Rom J Morphol Embryol; 2009; 50(3):413-8. PubMed ID: 19690767 [TBL] [Abstract][Full Text] [Related]
55. The Prognostic Significance of MACC1 Expression in Breast Cancer and Its Relationship to Immune Cells in the Tumor Microenvironment and Patient Survival. Ali DA; El-Guindy DM; Elrashidy MA; Sabry NM; Kabel AM; Gaber RA; Ibrahim RR; Samy SM; Shalaby MM; Salama SA; Abdelhai D Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577857 [TBL] [Abstract][Full Text] [Related]
56. Increased expression of FHL2 promotes tumorigenesis in cervical cancer and is correlated with poor prognosis. Jin X; Jiao X; Jiao J; Zhang T; Cui B Gene; 2018 Aug; 669():99-106. PubMed ID: 29800735 [TBL] [Abstract][Full Text] [Related]
57. Hypermethylation of Single CpG Dinucleotides at the Promoter of CXCL13 Gene Promoting Cell Migration in Cervical Cancer. Ma D; Fan SB; Hua N; Li GH; Chang Q; Liu X Curr Cancer Drug Targets; 2020; 20(5):355-363. PubMed ID: 31899677 [TBL] [Abstract][Full Text] [Related]
58. Changes in T lymphocyte subsets in peripheral blood of patients with middle-advanced cervical cancer before and after nimotuzumab combined with concurrent chemoradiotherapy. Ao M; Li P; Sun D; Li X; Xu S; Hao Y J Obstet Gynaecol; 2023 Dec; 43(1):2179915. PubMed ID: 37001548 [TBL] [Abstract][Full Text] [Related]
59. Low P16 Fu HC; Chuang IC; Yang YC; Chuang PC; Lin H; Ou YC; Chang Chien CC; Huang HS; Kang HY Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30150594 [TBL] [Abstract][Full Text] [Related]
60. A-kinase-interacting protein 1 promotes EMT and metastasis via PI3K/Akt/IKKβ pathway in cervical cancer. Zhang X; Liu S; Zhu Y Cell Biochem Funct; 2020 Aug; 38(6):782-791. PubMed ID: 32401379 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]